Loading...

Clincial Study Patient Recruitment and Site Engagement

Atopic Dermatitis

Stark Raving Branding and Digital Marketing

Targeting the Source of Painful Rash and Irritation

SponsorPfizer

 

IndicationAtopic Dermatitis

 

MaterialsPatient Outreach

 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention






Pfizer was conducting a phase 3 clinical study for its once-daily Janus kinase 1- (JAK1) selective inhibitor, PF-04965842, to evaluate the safety and efficacy of the drug for the treatment of moderate to severe atopic dermatitis (AD). AD, also commonly referred to as atopic eczema, is inflammation of the skin characterized by redness, itching, papulation, and crusting. This is the first clinical study in Pfizer’s JAK1 Atopic Dermatitis Efficacy and safety (JADE) global development program.

PF-04965842 is an oral small-molecule drug that selectively inhibits JAK1. The inhibition of JAK1 controls multiple cytokines involved in pathophysiology of AD including interleukin (IL)-4, IL-13, IL-31 and interferon gamma.
Data Sheet Design


White Paper Design


White Paper Detail


Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!